NLS Pharmaceutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a clinical-stage biopharmaceutical company, announced CEO Alex Zwyer will present at key investor conferences. The events include the Livingston Securities Healthcare and Emerging Growth CEO Series on February 25, 2021, at 11:30 AM ET and the Maxim 2021 Emerging Growth Virtual Conference on March 17, 2021. NLS is focused on developing treatments for rare central nervous system disorders, with its lead candidate Quilience®, a formulation of mazindol, targeting narcolepsy. The company has successfully completed a Phase 2 study for ADHD and holds Orphan Drug Designations in the U.S. and Europe.

STANS, Switzerland, Feb. 25, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present at the following upcoming investor conferences:

• Livingston Securities Healthcare and Emerging Growth CEO Series on Thursday, February 25, 2021 at 11:30am Eastern Time (5:30pm CET).
• Maxim 2021 Emerging Growth Virtual Conference hosted by M-Vest on March 17, 2021. The Company's presentation for this conference will be available on M-Vest following the conference.

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary controlled release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

Corporate contact 
Alex Zwyer, CEO: +41 41 618 80 00 

Investor Relations contact  
David Moskowitz: +1 202-280-0888 

www.nlspharma.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nls-pharmaceutics-to-participate-in-upcoming-investor-conferences-301235488.html

SOURCE NLS Pharmaceutics Ltd.

FAQ

When is the NLS Pharmaceutics investor conference presentation?

Alex Zwyer will present at the Livingston Securities Healthcare and Emerging Growth CEO Series on February 25, 2021, at 11:30 AM ET.

What date is the Maxim 2021 Emerging Growth Virtual Conference?

The Maxim 2021 Emerging Growth Virtual Conference is scheduled for March 17, 2021.

What is the lead product candidate of NLS Pharmaceutics?

NLS Pharmaceutics' lead product candidate is Quilience®, a controlled release formulation of mazindol, developed for narcolepsy.

What designations has Quilience® received?

Quilience® has received Orphan Drug Designations in both the U.S. and Europe for the treatment of narcolepsy.

What was the outcome of the Phase 2 study for mazindol CR?

The Phase 2 study for mazindol CR in adults with ADHD met all primary and secondary endpoints and was well-tolerated.